Skip to main content
Premium Trial:

Request an Annual Quote

Assurex Health Launches JV with Canadian Mental Health Center

NEW YORK (GenomeWeb News) – Assurex Health has created a public-private partnership with Canada's Centre for Addiction and Mental Health (CAMH) to offer the firm's pharmacogenomic test to help guide psychiatric treatments, the company said yesterday.

Assurex Health and CAMH have launched the joint venture AssureRx Canada to provide the GeneSight test, which measures and analyzes genomic variants to help physicians select the appropriate treatments for depression, anxiety, bipolar disorder, schizophrenia, and other neuropsychiatric conditions.

Mason, Ohio-based Assurex Health established AssureRx Canada as a subsidiary, and it shares equity ownership of the joint venture with CAMH. AssureRx Canada will maintain an office in Toronto and a certified clinical lab at the CAMH.

An initial project goal for the collaborators will be to use the GeneSight test with 20,000 patients in Ontario to improve their treatment outcomes and lower the cost of their healthcare.

Assurex Health and CAMH also plan to pursue validation and clinical studies to enhance the GeneSight test with new genetic markers. These new markers, discovered by CAMH, predict which individuals will experience rapid weight gain, a side-effect that affects many patients.

The GeneSight panel is reimbursed by "a number of insurance companies" and Medicare and Medicaid, the company said.

Assurex Health also said that data from the US shows a 70 percent improvement in depressive symptoms when the GeneSight test is used to predict patient response to antidepressants, as well as a 28 percent reduction in healthcare costs.

The Scan

Removal Inquiry

The Wall Street Journal reports that US lawmakers are seeking additional information about the request to remove SARS-CoV-2 sequence data from a database run by the National Institutes of Health.

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group says, according to the Financial Times.

Searching for More Codes

NPR reports that the US Department of Justice has accused an insurance and a data mining company of fraud.

Genome Biology Papers on GWAS Fine-Mapping Method, COVID-19 Susceptibility, Rheumatoid Arthritis

In Genome Biology this week: integrative fine-mapping approach, analysis of locus linked to COVID-19 susceptibility and severity, and more.